Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer
- PMID: 11301345
- DOI: 10.1038/modpathol.3880305
Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer
Abstract
Altered expression of the gene encoding the sodium iodine symporter (NIS) may be an important factor that leads to the reduced iodine accumulation characteristic of most benign and malignant thyroid nodules. Both up- and down-regulation of NIS gene expression have been reported in thyroid cancer using several different methods. The goal of the present study was to accurately identify alterations in NIS gene expression in benign and malignant thyroid nodules using an accurate real-time quantitative RT-PCR assay system. Total RNA was prepared from 18 benign thyroid nodules, 20 papillary thyroid cancers, and 23 normal thyroid samples from 38 subjects. Quantitative RT-PCR was used to measure NIS and thyroglobulin (TG) mRNA expression in normal thyroid tissue and in each nodular tissue sample. Papillary thyroid cancer samples had significantly lower NIS mRNA expression (72 +/- 41 picogram equivalents [pg Eq]), than did benign nodules (829 +/- 385 pg Eq), or normal tissues (1907 +/- 868 pg Eq, P = 0.04). Most important, in the paired samples, NIS gene expression was decreased in each papillary thyroid cancer compared with normal tissue (69% median decrease; range, 40-96%; P = .013). Eleven of the 12 benign nodules also demonstrated lower NIS gene expression than the normal tissue (49% decrease; range, 2-96%; P = .04). Analysis of the paired samples demonstrated that Tg mRNA expression was significantly lower in each of the thyroid cancer samples than in corresponding normal tissue (759 +/- 245 pg Eq vs. 1854 +/- 542 pg Eq, P = .03). We have demonstrated a significant decrement in NIS gene expression in all papillary thyroid cancers and in over 90% of benign nodules examined compared with adjacent normal thyroid tissue, using a highly accurate quantitative RT-PCR technique. Similarly, thyroid cancers demonstrated significantly lower TG mRNA expression than corresponding normal thyroid. Reduced NIS expression may be an important factor in the impairment of iodine-concentrating ability of neoplastic thyroid tissues.
Similar articles
-
Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.J Clin Endocrinol Metab. 2008 Oct;93(10):4141-5. doi: 10.1210/jc.2007-0353. Epub 2008 Jul 15. J Clin Endocrinol Metab. 2008. PMID: 18628528
-
Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.Thyroid. 2000 Mar;10(3):211-7. doi: 10.1089/thy.2000.10.211. Thyroid. 2000. PMID: 10779135
-
Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.J Clin Invest. 1998 Apr 1;101(7):1296-300. doi: 10.1172/JCI1259. J Clin Invest. 1998. PMID: 9525971 Free PMC article.
-
Sodium/iodide symporter mRNA expression in cold thyroid nodules.Exp Clin Endocrinol Diabetes. 2001;109(1):45-6. doi: 10.1055/s-2001-11013. Exp Clin Endocrinol Diabetes. 2001. PMID: 11573139 Review.
-
Implications of the molecular characterization of the sodium-iodide symporter (NIS).Exp Clin Endocrinol Diabetes. 1998;106 Suppl 3:S1-10. doi: 10.1055/s-0029-1212036. Exp Clin Endocrinol Diabetes. 1998. PMID: 9865544 Review.
Cited by
-
VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.World J Surg. 2015 Jul;39(7):1742-9. doi: 10.1007/s00268-015-3016-6. World J Surg. 2015. PMID: 25670042
-
Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer.Front Endocrinol (Lausanne). 2022 May 11;13:865909. doi: 10.3389/fendo.2022.865909. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35634509 Free PMC article.
-
Mathematical models applied to thyroid cancer.Biophys Rev. 2019 Apr;11(2):183-189. doi: 10.1007/s12551-019-00504-7. Epub 2019 Feb 15. Biophys Rev. 2019. PMID: 30771157 Free PMC article. Review.
-
Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?Br J Cancer. 2004 Jul 19;91(2):200-4. doi: 10.1038/sj.bjc.6601991. Br J Cancer. 2004. PMID: 15213710 Free PMC article. Review.
-
AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.Cancers (Basel). 2019 Jun 7;11(6):785. doi: 10.3390/cancers11060785. Cancers (Basel). 2019. PMID: 31181609 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous